Sezen Baglan Uzunget

Sezen Baglan Uzunget

Auto-generated profile, based on publicly available information

Sezen Baglan Uzunget


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2022 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
SUSezen Baglan Uzunget
Sezen Baglan Uzunget
KSKader Eliz Sahin
Kader Eliz Sahin
Background: In the latest reports, atherogenic indices have been related to acute coronary syndromes, stable coronary artery disease, heart failure and future cardiac events. Conventional atherosclerosis risk factors have been associated with mitral annular calcification (MAC), but data on the relationship between atherogenic indices and MAC are lacking. We aimed to investigate a possible relationship between MAC and atherogenic indices. Methods: In total 741 patients (n = 427 with MAC and n = 314 without MAC) who were examined in our cardiology clinic from February 2016 to October 2021 were recruited in the study. Mitral annular calcification was diagnosed by transthoracic 2-dimensional echocardiography. The atherogenic coefficient (AC), Castelli risk index 1 (CRI-1), Castelli risk index 2 (CRI-2) and atherogenic index of plasma (AIP) were calculated by utilizing standard lipid test values. Results: There was no statistically significant difference in sex, age, diabetes and hypertension status between the patient and the control groups. Serum triglyceride level, AIP, Hs-CRP, smoking and BMI were independently significantly associated with MAC in multiple regression analysis (p < 0.001). Conclusion: Higher AIP was related to the existence of MAC and also predict the presence of MAC independently. Studies evaluating the modification of these indices are needed.

12 March 2018 in Cardiology Research and Practice
Verified
Journal Article
Open access
PDF file
OKOzge Kurmus
Ozge Kurmus
TATurgay Aslan
Turgay Aslan
BEBerkay Ekici
Berkay Ekici
SUSezen Baglan Uzunget
Sezen Baglan Uzunget
SKSukru Karaarslan
Sukru Karaarslan
CKCelal Kervancıoglu
Celal Kervancıoglu
In patients with acute myocardial infarction, glucose metabolism is altered and acute hyperglycemia on admission is common regardless of diabetes status. The development of coronary collateral is heterogeneous among individuals with coronary artery disease. In this study, we aimed to investigate whether glucose value on admission is associated with collateral flow in ST-elevation myocardial infarction (STEMI) patients. We retrospectively evaluated 190 consecutive patients with a diagnosis of first STEMI within 12 hours of onset of chest pain. Coronary collateral development was graded according to Rentrop classification. Rentrop 0-1 was graded as poor collateral development, and Rentrop 2-3 was graded as good collateral development. Admission glucose was measured and compared between two groups. Mean admission glucose level was 173.0 ± 80.1 mg/dl in study population. Forty-five (23.7%) patients had good collateral development, and 145 (76.3%) patients had poor collateral development. There were no statistically significant differences in demographic characteristics between two groups. Three-vessel disease was more common in patients with good collateral development (p=0.026). Mean admission glucose level was higher in patients with poor collateral than good collateral (180.6 ± 84.9 mg/dl versus 148.7 ± 56.6 mg/dl, resp., p=0.008). In univariate analysis, higher admission glucose was associated with poor collateral development, but multivariate logistic regression analysis revealed a borderline result (odds ratio 0.994, 95% CI 0.989–1.000, p=0.049). Our results suggest that elevated glucose on admission may have a role in the attenuation of coronary collateral blood flow in acute myocardial infarction. Further studies are needed to validate our results.

1 March 2016
Verified
Journal Article
Open access
BSBARIS SENSOY
BARIS SENSOY
SUSezen Baglan Uzunget
Sezen Baglan Uzunget
SASadık Kadri Açıkgöz
Sadık Kadri Açıkgöz
NSNur Sensoy
Nur Sensoy
FSFatih Sen
Fatih Sen
OMOrhan Maden
Orhan Maden
No-reflow is a frequent complication during percutaneous coronary intervention (PCI) for acute ST segment elevation myocardial infarction (STEMI). Available data is limited regarding its impact on short-term outcomes in patients undergoing manual thrombus aspiration. Renal impairment is also associated with higher complication rates in STEMI. Herein, we aimed to evaluate the impact of baseline renal dysfunction on the no- reflow phenomenon and the association of no-reflow phenomenon with early clinical outcomes. A total of 94 consecutive STEMI patients who underwent primary stent-based PCI and thrombus aspiration were enrolled. No-reflow was established by the use of angiographic and electrocardiographic reperfusion criteria, respectively. Additionally angiographic and clinical follow-up data were also recorded. In our study, the no-reflow phenomenon was observed in 10 patients (11%) angiographically and in 23 patients (24%) electrocardiographically. Whereas, the the estimated glomerular filtration rate (eGFR) [odds ratio (OR) 10.4], hypertension (OR 6.2), previous MI (OR 6.5), previous PCI history, (OR 4.2), predilatation (OR 7.2), final balloon pressure (OR 0.9) were found to be the significant predictors of angiographic no-reflow, only reperfusion time was the predictor of electrocardiographic no-reflow (OR 1.12) at univariate analysis. After adjustment, lower eGFR (OR 14.8) was found to be the independent predictor for angiographic no-reflow. In-hospital mortality was more common in patients with either no-reflow condition separately. Longer ischemic time and lower initial eGFR values were associated with no-reflow phenomenon. Irrespective of poor reperfusion criteria, no-reflow phenomenon is associated with in-hospital outcome. Future efforts should be made to reduce the incidence of no-reflow especially in patients with lower initial eGFR values.

1 August 2018 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
SUSinan Cem Uzunget
Sinan Cem Uzunget
TETogay Evrin
Togay Evrin
SUSezen Baglan Uzunget
Sezen Baglan Uzunget
ZEZamir Kemal Ertürk
Zamir Kemal Ertürk
EAEgemen Akıncıoğlu
Egemen Akıncıoğlu
AKAtila Korkmaz
Atila Korkmaz


10 January 2025 in Anatolian Current Medical Journal
Verified
Journal Article
Open access
PDF file
AKAjar Koçak
Ajar Koçak
SUSezen Uzunget
Sezen Uzunget
KSKader Eliz Sahin
Kader Eliz Sahin
Aims: Beyond the acute phase of the COVID-19 disease, many patients experience persistent symptoms, collectively termed "post-COVID syndrome," which includes autonomic dysfunction. Heart rate variability (HRV) is a well-established method to assess autonomic nervous system (ANS) function. This study aimed to investigate the long-term impact of COVID-19 on autonomic function through evaluating the changes in HRV. Methods: This retrospective study included 225 participants divided into two groups: 117 post-COVID patients and 108 age and gender matched controls. HRV was assessed using 24-hour Holter monitoring. Time-domain and frequency-domain indices were analyzed, including standard deviation of normal-to-normal intervals (SDNN), root mean square of successive RR interval differences (RMSSD), and low frequency (LF)/high frequency (HF) ratio. Statistical comparisons were performed using independent t-tests, Mann-Whitney U tests, and correlation analyses. Results: Post-COVID patients exhibited significantly lower HRV indices compared to controls. Time-domain metrics such as SDNN (135.7±39.5 ms vs 149.1±34.2 ms, p=0.007) and RMSSD (32.7±13.7 ms vs 37.5±14.7 ms, p=0.012) were reduced in the COVID-19 group. Frequency-domain indices, including total power (TP) and HF power, were also diminished. Correlation analysis revealed no significant association between the duration of time post-COVID (one-year follow-up) and most HRV parameters. Conclusion: Post-COVID patients experience significant autonomic dysfunction, marked by reduced parasympathetic activity and increased cardiovascular risks, with some evidence of partial recovery during sleep. Routine HRV monitoring and targeted interventions, alongside further research with larger cohorts, are crucial for better understanding of the long-term effects and improving patient outcomes.